Making a major move in the obesity drug market, Pfizer (PFE)  announced on Monday that it plans to acquire biotechnology firm Metsera (MTSR)  by the end of the year for $4.9 billion or$47.50 a share.The deal has a potential value of up to $7.3 billion when including milestone-based payments of up to$22.50 per share, which would bring the total acquisition stock price for MTSR up to $70.In the wake of the news, Metsera stock has surged +60$50, with the price performance of Pfizer shares being vir ...